Respiratory Papillomatosis
Respiratory·MeSH: Recurrent respiratory papillomatosis
Prevalence
5.0 / 100K
10 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| papzimeos | PRECIGEN, INC. (PGEN) |
Phase 2(2)
Phase 1(5)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| ino-3107 | INOVIO PHARMACEUTICALS, INC. (INO) |
Phase 4(1)
| Drug | Company |
|---|---|
| Zopapogene imadenovec | PRECIGEN, INC. (PGEN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Respiratory Papillomatosis?
BioSniper tracks 10 drugs in development for Respiratory Papillomatosis across 2 companies.
How many clinical trials target Respiratory Papillomatosis?
There are 1 clinical trial targeting Respiratory Papillomatosis tracked by BioSniper.
What is the prevalence of Respiratory Papillomatosis?
The estimated prevalence of Respiratory Papillomatosis is approximately 5.0 per 100,000 population.
Deep-dive into Respiratory Papillomatosis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis